Drug Trial News

RSS

Nivolumab drug benefits metastatic RCC patients who continued treatment beyond progression

In a large randomized study, the immunotherapy drug nivolumab, a checkpoint inhibitor, was shown to be a safe and effective therapy for kidney cancer even in patients who continued treatment after their disease progressed.

7 Jun 2016

Pembrolizumab drug shows significant clinical responses in metastatic head and neck cancer patients

Treating head and neck cancer patients with recurrent or metastatic disease with the PD-1 inhibitor pembrolizumab resulted in significant clinical responses in a fifth of the patients from a phase II clinical trial, researchers at the Abramson Cancer Center of the University of Pennsylvania and other institutions reported at the 2016 American Society of Clinical Oncology annual meeting.

7 Jun 2016

Clinical study shows improved outcomes for NET patients treated with Lutathera over Octreotide LAR

NETTER-1 study, showing clinically meaningful and significant results for Lutathera (77Lu-DOTA0-Tyr3-Octreotate) in patients with metastatic midgut neuroendocrine tumors (NETs). The data will be presented Monday, June 6, during the American Society of Clinical Oncology Annual Meeting in Chicago.

6 Jun 2016

Targeted therapy rucaparib shows promise in treating pancreatic cancer patients with BRCA mutation

The targeted therapy rucaparib, which has demonstrated robust clinical activity in ovarian cancer patients with a BRCA mutation, also showed promise in previously treated pancreatic cancer patients with the mutation, according to results from a phase II clinical study presented by Susan M. Domchek, MD, executive director of the Basser Center for BRCA at the Abramson Cancer Center of the University of Pennsylvania, at the American Society of Clinical Oncology Annual Meeting.

6 Jun 2016

Experimental drug Rova-T shows safety, efficacy in treating advanced SCLC patients

The experimental "smart-bomb" drug rovalpituzumab tesirine (Rova-T) appears safe and shows efficacy in treating patients with advanced small cell lung cancer (SCLC), according to results from a first-in-human clinical trial to be presented today by a Memorial Sloan Kettering Cancer Center researcher at the 2016 American Society of Clinical Oncology Annual Meeting in Chicago.

6 Jun 2016

Nivolumab drug shows better response rate in metastatic bladder cancer patients

The immune checkpoint blockade drug nivolumab reduced tumor burden in 24.4 percent of patients with metastatic bladder cancer, regardless of whether their tumors had a biomarker related to the drug's target, according to clinical trial results from The University of Texas MD Anderson Cancer Center.

6 Jun 2016

New technique could help reduce chances of drug failure during later stages of clinical trials

An approach that could reduce the chances of drugs failing during the later stages of clinical trials has been demonstrated by a collaboration between the University of Cambridge and pharmaceutical company GlaxoSmithKline.

2 Jun 2016

Clinical trial to test safety, efficacy of Roswell Park-developed SurVaxM in multiple myeloma patients

An immune-based therapy developed at Roswell Park Cancer Institute is moving forward with its third clinical trial. The early-stage clinical trial will assess whether SurVaxM — a cancer vaccine developed at Roswell Park — is a safe and effective treatment option for patients with multiple myeloma, a rare type of blood cancer.

1 Jun 2016

$ART trial: Adacolumn shows clinical benefit in refractory ulcerative colitis patients$

ART trial: Adacolumn shows clinical benefit in refractory ulcerative colitis patients

Data from the 48-week ART trial, presented today at the Digestive Disease Week meeting, showed that remission and response rates were 37.2% and 53.2% respectively at week 12, in patients with moderate-to-severe, steroid-dependent active ulcerative colitis (UC) with insufficient response or intolerance to immunosuppressants and / or biologics when treated with between five and eight sessions with Adacolumn.

26 May 2016

First clinical trial to study use of Chinese Herbal Medicines in treating RUTIs

Researchers at the University of Southampton are to study the use of Chinese Herbal Medicines in treating recurrent urinary tract infections (RUTIs), in the first clinical trial of its kind in the UK.

25 May 2016

Clinical trials of anti-cancer agent PAC-1 continue to progress with anonymous funding

Clinical trials of the anti-cancer agent PAC-1 are continuing to expand, thanks to a $7 million angel investment from an anonymous contributor who originally invested $4 million to help get the compound this far in the drug-approval pipeline.

25 May 2016

Aliskiren fails to show benefit for heart failure patients with diabetes

A subgroup analysis in heart failure patients with diabetes from the ATMOSPHERE trial has failed to show benefit and signals the end of the road for aliskiren in heart failure.

24 May 2016

Investigational drug abemaciclib shows durable clinical activity for variety of cancer types

The investigational anticancer therapeutic abemaciclib, which targets CDK4 and CDK6, showed durable clinical activity when given as continuous single-agent therapy to patients with a variety of cancer types, including breast cancer, non-small cell lung cancer (NSCLC), glioblastoma, and melanoma, according to results from a phase I clinical trial.

23 May 2016

DECT trial shows combination of epirubicin and trastuzumab improves outcomes in breast cancer patients

The study entitled "A phase II neoadjuvant sequential regimen of docetaxel followed by high-dose epirubicin in combination with cyclophosphamide administered concurrently with trastuzumab.

23 May 2016

Phase I study of triple drug combination shows promise in multiple myeloma patients

PharmaMar announces the positive results from a Phase I study of plitidepsin in combination with bortezomib and dexamethasone in patients with relapsed and/or refractory multiple myeloma.

21 May 2016

High doses of vitamin D supplements could lead to fewer birth complications but reduce fertility

New research has established that high doses of vitamin D supplements can lead to fewer complications during childbirth but reduce a woman's chances of getting pregnant in the first place.

19 May 2016

Phase 2 results of AbbVie’s venetoclax in patients with R/R CLL with 17p deletion published in The Lancet Oncology

AbbVie, a global biopharmaceutical company, today announced The Lancet Oncology published results from the Phase 2, single arm, open label trial studying venetoclax in patients with relapsed/refractory (R/R) chronic lymphocytic leukaemia (CLL) with 17p deletion.

17 May 2016

Magic mushroom compound may offer potential new way for antidepressant research

Psilocybin – a hallucinogenic compound derived from magic mushrooms – may offer a possible new avenue for antidepressant research, according to a new study published in The Lancet Psychiatry today.

17 May 2016

Boehringer Ingelheim presents new data on OFEV® (nintedanib) in idiopathic pulmonary fibrosis (IPF)

New analyses presented at the American Thoracic Society’s 2016 annual conference (ATS 2016) further add to the efficacy and safety profile of OFEV® (nintedanib) in idiopathic pulmonary fibrosis (IPF).

16 May 2016

NeuroDerm starts patient enrollment in long-term safety study of ND0612 for treatment of Parkinson’s disease

NeuroDerm Ltd., a clinical stage pharmaceutical company developing drugs for central nervous system disorders, today announced the start of patient enrollment in a long-term safety study (trial 012) of the company’s continuously administered subcutaneous levodopa/carbidopa formulation used in both ND0612H and ND0612L.

13 May 2016

Drug Trial News

Nivolumab drug benefits metastatic RCC patients who continued treatment beyond progression

Pembrolizumab drug shows significant clinical responses in metastatic head and neck cancer patients

Clinical study shows improved outcomes for NET patients treated with Lutathera over Octreotide LAR

Targeted therapy rucaparib shows promise in treating pancreatic cancer patients with BRCA mutation

Experimental drug Rova-T shows safety, efficacy in treating advanced SCLC patients

Nivolumab drug shows better response rate in metastatic bladder cancer patients

New technique could help reduce chances of drug failure during later stages of clinical trials

Clinical trial to test safety, efficacy of Roswell Park-developed SurVaxM in multiple myeloma patients

ART trial: Adacolumn shows clinical benefit in refractory ulcerative colitis patients

First clinical trial to study use of Chinese Herbal Medicines in treating RUTIs

Clinical trials of anti-cancer agent PAC-1 continue to progress with anonymous funding

Aliskiren fails to show benefit for heart failure patients with diabetes

Investigational drug abemaciclib shows durable clinical activity for variety of cancer types

DECT trial shows combination of epirubicin and trastuzumab improves outcomes in breast cancer patients

Phase I study of triple drug combination shows promise in multiple myeloma patients

High doses of vitamin D supplements could lead to fewer birth complications but reduce fertility

Phase 2 results of AbbVie’s venetoclax in patients with R/R CLL with 17p deletion published in The Lancet Oncology

Magic mushroom compound may offer potential new way for antidepressant research

Boehringer Ingelheim presents new data on OFEV® (nintedanib) in idiopathic pulmonary fibrosis (IPF)

NeuroDerm starts patient enrollment in long-term safety study of ND0612 for treatment of Parkinson’s disease

Unlocking live single-cell functional insights

Fluidics in Modern Healthcare & Medical Device Innovation

How microRNA is transforming science: From discovery to diagnostics

Latest News